NCT05358873View on ClinicalTrials.gov

Efficacy and Safety of Nasal Spray Solution Containing Human IgG1 Anti-COVID-19 Antibody Cocktail

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 20, 2022

Primary Completion Date

July 1, 2022

Study Completion Date

July 1, 2022

Conditions
SARS CoV 2 InfectionSARS-CoV-2 Acute Respiratory Disease
Interventions
DEVICE

Human IgG1 anti-SARS-CoV-2 antibody cocktail

Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail

DEVICE

Placebo

Normal saline

Trial Locations (1)

10400

National Cancer Institute of Thailand, Bangkok

Sponsors
All Listed Sponsors
collaborator

Ramathibodi Hospital

OTHER

collaborator

Ever Medical Technology Co., Ltd.

UNKNOWN

collaborator

The Government Pharmaceutical Organization

OTHER_GOV

collaborator

Ministry of Health, Thailand

OTHER_GOV

collaborator

HIBIOCY CO., Ltd.

UNKNOWN

lead

Chulalongkorn University

OTHER